Disorders of the basal ganglia and their modern management

Journal of the Royal College of Physicians of London

Volumn 33, Issue 4, 1999, Pages 323-327

  Schrag, Anette ^b   Quinn, Niall ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BACLOFEN; BENSERAZIDE PLUS LEVODOPA; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; BROMOCRIPTINE; CABERGOLINE; CARBAMAZEPINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PRAMIPEXOLE; PRIMIDONE; PROPRANOLOL; ROPINIROLE; SELEGILINE;

BASAL GANGLION; CHOREA; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DYSKINESIA; DYSTONIA; ESSENTIAL TREMOR; HUMAN; HUNTINGTON CHOREA; INTRAMUSCULAR DRUG ADMINISTRATION; PARKINSON DISEASE; PARKINSONISM; SHORT SURVEY; SIDE EFFECT; STEREOTAXIC SURGERY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIPARKINSON AGENTS; BASAL GANGLIA DISEASES; DOPAMINE AGENTS; DYSTONIA; HUMANS; HUNTINGTON DISEASE; LEVODOPA; PARKINSON DISEASE;

EID: 0032869457     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. Ben-Shlomo Y. The epidemiology of Parkinson's disease. Baillière's Clin Neurol 1997;6:55-68.
2. Tanner CM, Ottman R, Goldman SM, Ellenberg J, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-6.
3. Chase TN, Engber TM, Mouradian MM. Pathogenetic studies of motor response complications in levodopa-treated patients with advanced Parkinson's disease. In: Rinne UK, Nagatsu T, Horowski R (eds). International Workshop Berlin, Parkinson's Disease. Bussum: Medicom Europe, 1991:197.
4. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37:23-7.
5. Dupont E, Andersen A, Boas J, Boisen E, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996;93:14-20.
6. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-8.
7. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. Br Med J 1995;311:1602-7.
8. Nutt JG. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet 1998;351:1221-2.
9. Quinn N, Bhatia K. Functional neurosurgery for Parkinson's disease. Br Med J 1998;316:1259-60.
10. Gill SS, Heywood P. Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease. Lancet 1997; 350:1224.
11. Limousin P, Krack P, Pollak P, Benazzouz A, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339:1105-11.
12. McKeith IG, Galasko D, Kosaka K, Perry EK, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
13. Wenning GK, Quinn NP. Multiple system atrophy. Baillière's Clin Neurol 1997;6: 187-204.
14. Litvan I, Agid Y, Calne D, Campbell G, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
15. Louis ED, Ford B, Wendt KJ, Cameron G. Clinical characteristics of essential tremor: data from a community-based study. Mov Disord 1998;13:803-8.
16. Chouinard S, Louis ED, Fahn S. Agreement among movement disorder specialists on the clinical diagnosis of essential tremor. Mov Disord 1997;12: 973-6.
17. Benabid AL, Benazzouz A, Hoffmann D, Limousin P, et al. Long-term electrical inhibition of deep brain targets in movement disorders. Mov Disord 1998;13(Suppl 3):119-25.
18. Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol 1998;78:1-10.
19. Bandmann O, Valente EM, Holmans P, Surtees RA, et al. Dopa-responsive dystonia: a clinical and molecular genetic study. Ann Neurol 1998;44:649-56.
20. Jankovic J. Medical therapy and botulinum toxin in dystonia. Adv Neurol 1998;78:169-83.
21. Lang AE. Surgical treatment of dystonia. Adv Neurol 1998;78:185-9.